Ongoing since 2020
Company Overview
Innovation: Therapeutics—first-in-class botanical cancer platform drug
Targeted Cancer(s): Liver cancer
Scientific Leadership: Yung-Chi Cheng, Ph.D.; Shwu-Huey Liu, Ph.D.
Stage of Project: Phase II clinical trial about to commence; orphan drug designations granted by the U.S. Food and Drug Administration (FDA)
Opportunity
YIV-906 is a botanical cancer drug that…
![](https://afcr.org/wp-content/uploads/2016/05/Chinese-Medicine-teaser.jpg)